GLP-1 medications work by copying a natural gut hormone that lowers hunger, increases fullness and slows how quickly the stomach empties. They also help the pancreas release insulin, but only when blood sugar is high.
Tirzepatide also acts on a second hormone receptor, GIP, which is one way it differs from semaglutide.
This guide explains how GLP-1 medications work on appetite, digestion and blood sugar, who may be evaluated for them, which warnings and side effects are reviewed, and what can change after treatment stops.
| Product | Active ingredient | Receptor targets | Weight-management indication |
|---|---|---|---|
| Wegovy® | Semaglutide | GLP-1 | Yes, for defined populations |
| Zepbound® | Tirzepatide | GIP and GLP-1 | Yes, plus sleep apnea in certain adults |
| A semaglutide product approved for type 2 diabetes | Semaglutide | GLP-1 | No |
| A tirzepatide product approved for type 2 diabetes | Tirzepatide | GIP and GLP-1 | No |
In this article
What Are GLP-1 Medications?
GLP-1 medications, also called GLP-1 receptor agonists, are prescription medicines designed to act like glucagon-like peptide-1, a hormone the intestine releases after you eat. Semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) are the best-known examples, and most are taken as an injection once a week.
Some are approved for type 2 diabetes and others for chronic weight management. The weight-management products are prescribed for adults with obesity, or with overweight plus a weight-related health condition, alongside changes to eating and activity.
GLP-1, appetite and stomach emptying
What is GLP-1?
GLP-1 is an incretin hormone released from the intestine after eating. It helps the pancreas release insulin when glucose is elevated, reduces glucagon signaling in a glucose-dependent way, slows gastric emptying and communicates satiety to the brain.
Native GLP-1 is broken down quickly. Prescription GLP-1 receptor agonists are designed to activate the same receptor for longer. Their structures, approved indications, delivery routes and dosing instructions differ by product.
Some branded medicines activate more than one incretin pathway, including both GIP and GLP-1 receptors. That class distinction is a pharmacology fact, not evidence that one drug is automatically suitable or superior for a particular person.
How does appetite signaling change?
GLP-1 receptors in the brain and digestive system participate in hunger and satiety. Activating them can make a person feel full sooner, reduce persistent food thoughts or decrease interest in large portions. The experience is not identical for everyone.
Reduced appetite can help create an energy deficit, but eating too little can also reduce protein, fluid, fiber and micronutrient intake. Nausea or early fullness should not be mistaken for proof that treatment is working well.
The clinician reviews eating pattern, hydration, strength, activity and symptoms. Weight management remains broader than appetite suppression.
Why does gastric emptying matter?
Gastric emptying describes how food moves from the stomach into the small intestine. GLP-1 receptor activation can slow this process, especially early in treatment. Slower emptying contributes to fullness and can also contribute to nausea, reflux, bloating or vomiting.
Severe or persistent gastrointestinal symptoms need clinical review. Repeated vomiting can cause dehydration and kidney injury. Intense abdominal pain, particularly with vomiting, can signal a condition requiring urgent assessment.
Delayed gastric emptying also matters before anesthesia or deep sedation. The procedural and prescribing teams need an accurate medication history and decide how current guidance applies. A person should not invent a stop schedule from online advice.
Blood sugar, semaglutide and tirzepatide
How do these medicines affect glucose?
GLP-1 signaling increases insulin release when blood glucose is elevated and reduces glucagon in a glucose-dependent manner. Used alone, that physiology differs from medicines that drive insulin regardless of glucose.
Low blood sugar risk can rise when a GLP-1 medicine is combined with insulin or a sulfonylurea. The clinician may need to review diabetes treatment and monitoring. Symptoms such as sweating, shakiness, confusion or weakness require an appropriate response plan.
Weight-management and diabetes indications must stay distinct. A brand approved for type 2 diabetes should not be presented as approved for weight management unless that exact product label carries the indication.
Which products have weight-management indications?
Wegovy® (semaglutide) is an FDA-approved brand with chronic weight-management labeling for defined populations. Zepbound® (tirzepatide) is also FDA-approved for chronic weight management. It carries an additional indication for certain adults with obesity and moderate-to-severe obstructive sleep apnea.
Semaglutide and tirzepatide are also sold under separate brand names approved for type 2 diabetes. Sharing an active ingredient does not make brands interchangeable. Product identity, label, strength and instructions remain exact.
Compounded medicines and prescription eligibility
Where does compounded semaglutide or tirzepatide fit?
Compounded medications are prepared by a licensed pharmacy for an individual patient and are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they reach patients. Compounded medications are not generic versions of, and have not been shown to be equivalent to, any FDA-approved drug.
Through Atlas HRT, an independent Florida-licensed physician decides whether Zepbound, Wegovy or a compounded semaglutide or tirzepatide fits, and a licensed partner pharmacy dispenses any prescription. The compounded GLP-1 safety information sets out the risks for that route.
Who may be evaluated for weight-management medication?
Product labels use BMI and weight-related health conditions among their criteria. A numerical category opens a clinical question; it does not create automatic eligibility. Pregnancy plans, medical history, medicines, contraindications, prior reactions and follow-up ability remain relevant.
Evaluation covers weight history, blood pressure, diabetes, sleep apnea, cardiovascular health, kidney and liver health, nutrition and mental health. Unintentional weight loss needs a different investigation.
The medical weight-loss evaluation guide walks through this assessment step by step.
GLP-1 warnings and side effects
What contraindications and warnings are reviewed?
Current labels carry boxed warnings related to thyroid C-cell tumors observed in rodents and contraindications for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The relevance and exact wording must follow the specific product label.
Clinicians also review pancreatitis history, gallbladder disease, severe gastrointestinal disease, kidney risk from dehydration, diabetic retinopathy context for selected products, allergies and interactions. Each product has its own label.
Pregnancy is a major boundary. Weight loss offers no benefit during pregnancy and may cause fetal harm. Conception plans and label-specific discontinuation timing belong in the prescribing discussion.
What adverse effects are common?
Nausea, diarrhea, vomiting, constipation and abdominal discomfort occur commonly across the class. Symptoms often change over time, but no timeline or degree of tolerance can be promised.
Reduced intake can worsen dehydration, dizziness or inadequate nutrition. Persistent vomiting, inability to keep fluids down, severe abdominal pain, signs of allergic reaction or symptoms of low glucose require timely medical attention.
The clinician distinguishes manageable effects from a reason to reassess treatment. Changes to treatment, meals or symptom care come from the prescribing physician.
What are gallbladder and pancreas concerns?
Rapid weight change and GLP-1 treatment can occur alongside gallbladder events such as gallstones or gallbladder inflammation. Right-upper-abdominal pain, fever, jaundice or persistent symptoms deserve medical assessment.
Acute pancreatitis has been reported with products in this class. Persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting, requires prompt evaluation. Only a clinical assessment can identify the cause.
Past pancreatitis and gallbladder history should be disclosed before a treatment decision. The clinician interprets risk using the exact product label and health context.
How do nutrition and muscle preservation fit?
When appetite falls, total food and protein intake can fall too. A plan should protect adequate nutrition rather than celebrate the smallest possible intake. Hydration, fiber and micronutrient needs also matter.
Resistance training and appropriate protein intake are considerations for strength and lean-tissue retention during weight management. Physical limitations, kidney disease and other conditions may change the advice, so no universal target applies.
Monitoring should look beyond body weight. Strength, function, dietary adequacy, gastrointestinal symptoms and quality of life can reveal whether the plan is sustainable.
Nutrition, stopping GLP-1 treatment and follow-up
What can change after GLP-1 treatment ends?
Obesity is a chronic disease, and appetite or weight can change after medication ends. The amount and timing vary. Stopping does not prove failure, and continuing should not be assumed without ongoing review.
The clinician discusses maintenance support, nutrition, activity, other health conditions and why treatment is ending. A sudden self-directed change can complicate glucose management or symptoms.
Long-term planning belongs in the initial conversation because short-term product use does not erase the biology that contributed to weight gain.
How is progress monitored?
Follow-up reviews weight trend, appetite, nutrition, hydration, gastrointestinal symptoms, activity, mood, pregnancy plans and relevant laboratory or health measures. Diabetes medicines and glucose data may require particular attention.
The clinician also checks whether treatment goals remain realistic and clinically meaningful. Lack of benefit, unacceptable effects or a new contraindication can change the plan.
Atlas HRT wellness consultants can support access and logistics but do not calculate product eligibility, choose a drug or adjust treatment.
We think understanding how GLP-1 medications work makes people better patients. Knowing they slow digestion and quiet hunger explains the side effects, why doses rise slowly and why eating habits still matter. It is a tool that works with you, not a switch that works alone.
Common questions
Do GLP-1 medicines act directly on fat tissue?
They primarily change appetite, satiety, digestion and glucose signaling. Reduced energy intake can contribute to weight loss over time.
Do they work without nutrition or activity support?
Medication can change biology, but adequate nutrition, movement, sleep and management of related conditions remain important for health and maintenance.
Is the product with the largest trial result best?
Not automatically. Indication, contraindications, tolerability, interactions, preferences and individual response determine fit.
Atlas HRT Team
Reviewed by · Last reviewed September 2026Atlas HRT specializes in GLP-1 medications for medical weight loss for adults in Florida.
Sources
- Obesity: GLP-1 therapies, World Health Organization
- FDA compounding questions and answers, U.S. Food and Drug Administration
- FDA concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration
- Zepbound prescribing information, Eli Lilly; accessed October 10, 2026
